Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Apr;34(4):524–528. doi: 10.1128/aac.34.4.524

In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

G S Kobayashi 1, S J Travis 1, M G Rinaldi 1, G Medoff 1
PMCID: PMC171637  PMID: 2344160

Abstract

The antifungal activities of amphotericin B and two triazoles, Sch 39304 and fluconazole, were tested against Histoplasma capsulatum. In this study Sch 39304 compared favorably with amphotericin B in treating histoplasmosis in normal and leukopenic mice, whereas fluconazole was much less active. The differences in the efficacies of the triazoles appeared to be due to differences in their pharmacokinetics and the dosage schedule that was used. For amphotericin B there was a good correlation between in vitro and in vivo efficacy, but this was not true of the triazole derivatives. These results further demonstrate that, with the methods used in this study, in vitro susceptibility testing of triazoles may not be predictive of in vivo activity against isolates of H. capsulatum.

Full text

PDF
526

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cryz S. J., Jr, Fürer E., Germanier R. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun. 1983 Mar;39(3):1067–1071. doi: 10.1128/iai.39.3.1067-1071.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dupont B., Drouhet E. Cryptococcal meningitis and fluconazole. Ann Intern Med. 1987 May;106(5):778–778. doi: 10.7326/0003-4819-106-5-778_2. [DOI] [PubMed] [Google Scholar]
  3. Fromtling R. A. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988 Apr;1(2):187–217. doi: 10.1128/cmr.1.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Galgiani J. N. Antifungal susceptibility tests. Antimicrob Agents Chemother. 1987 Dec;31(12):1867–1870. doi: 10.1128/aac.31.12.1867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Graybill J. R., Palou E., Ahrens J. Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis. 1986 Oct;134(4):768–770. doi: 10.1164/arrd.1986.134.4.768. [DOI] [PubMed] [Google Scholar]
  6. Graybill J. R., Sun S. H., Ahrens J. Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol. 1986 Apr;24(2):113–119. doi: 10.1080/02681218680000171. [DOI] [PubMed] [Google Scholar]
  7. Harris S. C., Wallace J. E., Foulds G., Rinaldi M. G. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother. 1989 May;33(5):714–716. doi: 10.1128/aac.33.5.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hughes C. E., Bennett R. L., Tuna I. C., Beggs W. H. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother. 1988 Feb;32(2):209–212. doi: 10.1128/aac.32.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kobayashi G. S., Little J. R., Medoff G. In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester. Antimicrob Agents Chemother. 1985 Mar;27(3):302–305. doi: 10.1128/aac.27.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kobayashi G. S., Travis S. J., Medoff G. Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice. Antimicrob Agents Chemother. 1987 Dec;31(12):2005–2006. doi: 10.1128/aac.31.12.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kobayashi G. S., Travis S., Medoff G. Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother. 1986 Apr;29(4):660–662. doi: 10.1128/aac.29.4.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lyman C. A., Sugar A. M., Diamond R. D. Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice. Antimicrob Agents Chemother. 1986 Jan;29(1):161–162. doi: 10.1128/aac.29.1.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Palou de Fernandez E., Patino M. M., Graybill J. R., Tarbit M. H. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother. 1986 Aug;18(2):261–270. doi: 10.1093/jac/18.2.261. [DOI] [PubMed] [Google Scholar]
  14. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  15. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Polak A., Dixon D. M. Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49,858) against histoplasma capsulatum in vitro and in vivo. Mykosen. 1987 Apr;30(4):186–194. doi: 10.1111/j.1439-0507.1987.tb03967.x. [DOI] [PubMed] [Google Scholar]
  17. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Savani D. V., Perfect J. R., Cobo L. M., Durack D. T. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987 Jan;31(1):6–10. doi: 10.1128/aac.31.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shadomy S., White S. C., Yu H. P., Dismukes W. E. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis. 1985 Dec;152(6):1249–1256. doi: 10.1093/infdis/152.6.1249. [DOI] [PubMed] [Google Scholar]
  22. Spitzer E. D., Travis S. J., Kobayashi G. S. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):80–81. doi: 10.1007/BF01962183. [DOI] [PubMed] [Google Scholar]
  23. Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Troke P. F., Andrews R. J., Marriott M. S., Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother. 1987 May;19(5):663–670. doi: 10.1093/jac/19.5.663. [DOI] [PubMed] [Google Scholar]
  25. Wheat L. J. Systemic fungal infections: diagnosis and treatment. I. Histoplasmosis. Infect Dis Clin North Am. 1988 Dec;2(4):841–859. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES